@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix schem: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix species: . @prefix occursIn: . @prefix mesh: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:12680; a Protein: . sub:_2 occursIn: mesh:D005347, species:9606; rdf:object sub:_1; rdf:predicate belv:decreases; rdf:subject schem:ZD6474; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:ZD6474) -| p(HGNC:VEGFA)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_4; pav:version "1.4" . sub:_3 prov:value "ZD6474 is also a potent inhibitor of KDR, the vascular endothelial growth factor (VEGF) receptor, and thus exerts anti-angiogenic effects [90]. The arylidene 2-indolinone RPI-1 was effective against RET but only at high doses (IC50 in the micromolar range)"; prov:wasQuotedFrom pubmed:15583857 . sub:_4 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:15583857; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:30:30.124+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }